Reagena Receives The 2023 Customer Value Leadership Award
Reagena has been identified as best in class in the European zoonoticpoint-of-care diagnostic...
Read more Reagena Receives The 2023 Customer Value Leadership AwardNews
AACC 2022
Reagena offers EIA and rapid diagnostic kits for the tick transmitted diseases. If you wish to...
Read more AACC 2022
CE IVDR marked formalines from Reagena
Reagena’s formalines, which are CE-marked under IVDR, straight from our stock. Reagena’s...
Read more CE IVDR marked formalines from Reagena
Reagena exhibits at ECCMID 2022
We invite you to meet us in the 32nd European Congress of Clinical Microbiology & Infectious...
Read more Reagena exhibits at ECCMID 2022
Labquality Days 20.-21.4.2022
Reagena participates in Labquality Days 2022. The conference and exhibition will take place on...
Read more Labquality Days 20.-21.4.2022
Recent ReaScan+ C6 LYME IgG publication
Clinical performance and analytical accuracy of a C6 peptide-based point-of-care lateral flow...
Read more Recent ReaScan+ C6 LYME IgG publication
Medica 2021 in Düsseldorf
Reagena exhibits at Medica 2021 in Düsseldorf, Germany on November 15-18th. We invite you...
Read more Medica 2021 in Düsseldorf
ReaScan CXCL13 publication
CXCL13 in laboratory diagnosis of Lyme neuroborreliosis - the performance of the recomBead and...
Read more ReaScan CXCL13 publication
ReaScan+ C6 LYME IgG rapid test developed by Reagena
ReaScan+ C6 LYME IgG is an immunochromatographic rapid test intended for qualitative detection of Borrelia burgdorferi specific IgG antibodies in human serum and cerebrospinal fluid (CSF)
Read more ReaScan+ C6 LYME IgG rapid test developed by Reagena
Frost & Sullivan recognized Reagena as ’European zoonotic point-of-care diagnostic company of the year 2020’
Year 2020 award was earned by Reagena’s pioneering leadership in further advancing rapid...
Read more Frost & Sullivan recognized Reagena as ’European zoonotic point-of-care diagnostic company of the year 2020’